AI Consensus Investment Thesis
MRK: Merck & Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Merck &: 1-Year and 5-Year Forecast Outlook and Rating
Merck & (MRK) has an immediate Hold & Monitor consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $156 for , with +5.19% expected return (+6.73% including net dividends) and a NEUTRAL rating.
The 5-year target is $167 for , with +12.61% expected return (+21.77% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 148, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.6%. As of 2026-10-20.
Gross TTM: 2.29% · Two-year annualized gross: 2.24%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 2.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Merck & Flagship Insight
Patent Cliff Countdown Tests Biopharma Fortress Valuation and Lifecycle Defense
Sharp divergence defines the investment consensus. A massive sixteen billion dollar free cash flow engine and rapid subcutaneous adoption confront a late-2028 patent cliff on half of group revenue, while early 2026 GAAP losses reflect upfront acquisitions rather than underlying operational decay.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Superintelligence (Anthropologist)
Sherlock Holmes (Whistleblower)
J.P. Morgan (Titan)
Michael Burry (Vulture)
Universal Investor (Polymath)
Elon Musk (Visionary)
Ray Dalio (Strategist)
Machiavelli (Insider)
Warren Buffett (Value Purist)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Merck &: forecast questions
What is Merck & (MRK)'s 1-year price forecast?
Merck &'s 1-year target is $156 for Sept 2027. The current AI rating is NEUTRAL. The expected return from the recorded close is +5.19%, or +6.73% modeled return including net dividends. Latest available market price: USD 148, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Merck & (MRK)'s 5-year price forecast?
Merck &'s 5-year target is $167 for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +12.61%, or +21.77% modeled return including net dividends. Latest available market price: USD 148, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 148, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Merck & forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Merck & differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Merck & is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Merck &: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Merck & at the latest market close (20 Oct 2026): $12,177 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
* Return is calculated incl. 1.6% net dividend yield for Merck &.
The base-case thesis hinges on navigating the impending late-2028 loss of exclusivity on Keytruda, which represents nearly half of group revenue. The market has rewarded the company with multiple expansion from nine times forward earnings to seventeen times on essentially flat underlying profit, driven by defensive rotation amid persistent inflation and high sovereign yields. Core cash generation remains formidable, with trailing free cash flow exceeding sixteen billion dollars, while early 2026 GAAP losses were driven by fourteen point seven billion dollars of upfront acquired research charges rather than operational decay. The critical valuation risk is that investors have already paid for the crossing of the 2028 chasm. If commercial payers mandate step-therapy with sixty percent discounted intravenous biosimilars over premium subcutaneous formulations, multiple compression will compound operational revenue erosion. However, substantial scaling across Winrevair, oral PCSK9 inhibitor Lipfendra, and partnered antibody-drug conjugates establishes a durable replacement baseline that prevents structural balance-sheet distress.
Key insights
- Subcutaneous reformulation defends oncology cash flows only if commercial payers accept convenience over sixty percent intravenous biosimilar discounts.
- Upfront acquisition accounting write-offs artificially distort GAAP optics, masking resilient underlying owner earnings and robust sixteen billion dollar cash conversion.
- Premium valuation multiples acquired via defensive macro rotation remain highly vulnerable to unwinding once disinflation restores capital flows to growth sectors.
Merck &: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 148, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.6%. As of 2026-10-20.
Gross TTM: 2.29% · Two-year annualized gross: 2.24%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 2.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 147. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $148 | +0.90% | -0.20% | +0.05% | Third-quarter operational reporting shows clean non-GAAP earnings as upfront transaction charges subside. Winrevair sales acceleration and subcutaneous conversion gains drive modest appreciation, partially tempered by elevated Treasury yields keeping defensive multiples in check. | $142 | $151 | $750 | |
| $151 | +1.98% | +1.82% | +2.48% | Full-year disclosures confirm underlying free cash flow exceeding fifteen billion dollars. However, preliminary publication of Medicare drug price negotiation frameworks and scrutiny over subcutaneous inclusion induce valuation caution, producing limited net equity movement. | $135 | $157 | $736 | |
| $154 | +2.18% | +3.84% | +4.94% | Solid medical congress presentations on partnered oncology pipelines and accelerating global cardiopulmonary adoption provide fundamental reassurance. Operating margin stabilization offsets macrofinancial headwinds, supporting a modest, steady recovery across institutional healthcare allocations. | $139 | $162 | $743 | |
| $156 | +1.21% | +5.19% | +6.73% | Subcutaneous formulation conversion reaches targeted twenty percent clinic adoption thresholds, validating initial lifecycle defensibility. Shares consolidate as investors balance robust current cash generation against the approaching twelve-month pre-cliff regulatory window. | $140 | $165 | $755 | |
| $157 | +0.74% | +5.87% | +7.84% | Annual dividend increases and programmatic repurchases reinforce total return support. Commercial strength in non-oncology franchises offsets lingering international vaccine demand softness, allowing defensive institutional capital to preserve stable equity valuation levels. | $134 | $170 | $776 | |
| $156 | -1.03% | +5.19% | +7.58% | Pre-cliff de-risking accelerates as market focus fixes onto the impending loss of exclusivity. Initial biosimilar filings and cautious guidance framing prompt multiple contraction, outweighing resilient operational cash generation across commercial lines. | $127 | $174 | $787 | |
| $155 | -0.71% | +4.52% | +7.32% | Statutory Medicare price negotiation lists and hospital procurement reviews create temporary headline friction. While cardiopulmonary blockbusters expand, institutional investors demand higher risk premia ahead of fourth-quarter intravenous patent expirations, causing mild slippage. | $122 | $175 | $803 | |
| $151 | -2.11% | +1.82% | +4.97% | Valuation multiples compress as the final patented quarter for intravenous pembrolizumab begins. Subcutaneous conversion advances toward thirty-five percent, yet cautious market participants reduce exposure ahead of immediate commercial biosimilar entry. | $119 | $174 | $812 | |
| $147 | -2.84% | -0.88% | +2.60% | Primary composition-of-matter patent protection lapses in the United States, prompting reflexive headline selling. Competing biosimilars receive regulatory clearance, triggering institutional portfolio adjustments despite substantial oncology volume remaining ring-fenced by subcutaneous presentations. | $111 | $174 | $839 | |
| $145 | -1.69% | -2.23% | +1.60% | Initial commercial biosimilar launches trigger price discounting across hospital accounts, establishing the earnings transition trough. Subcutaneous retention cushions top-line erosion, reassuring deep-value investors that cash flows will avoid a catastrophic cliff. | $104 | $177 | $851 | |
| $145 | +0.02% | -2.23% | +2.01% | Second-quarter results confirm intravenous oncology margin contraction is tracking within expected limits. Expanding contributions from Winrevair, Lipfendra, and pneumococcal vaccines establish an operational plateau, halting downward earnings estimate revisions. | $98.5 | $182 | $872 | |
| $146 | +0.69% | -1.55% | +3.12% | Diversified pipeline revenue crosses critical mix thresholds, demonstrating tangible gross profit substitution. Value-oriented institutional buyers step in as high free cash flow conversion and defensive yields provide a firm valuation floor. | $94.5 | $186 | $886 | |
| $148 | +1.71% | -0.20% | +4.95% | Full-year execution validates the durability of non-oncology pillars, and management reiterates dividend coverage discipline. The cessation of negative earnings revisions prompts modest multiple stabilization into year-end portfolio positioning. | $91.7 | $190 | $910 | |
| $151 | +1.97% | +1.82% | +7.50% | Annual reporting confirms the structural earnings trough has passed without credit impairment. Operating cost rationalization takes full effect, enabling per-share earnings to rebound faster than consolidated revenues and initiating renewed accumulation. | $93.5 | $194 | $916 | |
| $154 | +1.96% | +3.84% | +10.08% | Phase 3 readouts for partnered antibody-drug conjugates and expanded cardiometabolic indications de-risk the long-term pipeline. Growing non-pembrolizumab sales prompt sell-side analysts to lift terminal growth assumptions, driving steady appreciation. | $91.6 | $197 | $937 | |
| $157 | +1.66% | +5.87% | +12.67% | Operating margins recover toward thirty-four percent as commercial manufacturing efficiencies scale. Restored balance-sheet capacity allows management to expand share repurchases, enhancing per-share cash compounding across defensive institutional holdings. | $94.4 | $195 | $947 | |
| $159 | +1.61% | +7.22% | +14.56% | Anticipation of upcoming European exclusivity loss in 2031 introduces localized caution, but strong domestic execution in cardiometabolic and specialty franchises cushions sentiment, supporting modest net equity price gains. | $96.3 | $199 | $970 | |
| $162 | +1.53% | +9.24% | +17.18% | European biosimilar competition arrives in an orderly fashion against established subcutaneous market share. High-margin revenue from mature specialty blockbusters keeps consolidated cash flow resilient, preventing substantial valuation slippage. | $93.4 | $201 | $980 | |
| $164 | +1.51% | +10.59% | +19.10% | Non-Keytruda therapies generate over sixty percent of consolidated pharmaceutical revenue, verifying successful portfolio transformation. Improving broader liquidity conditions support modest multiple expansion as patent cliff overhangs permanently recede. | $95.3 | $205 | $1,000 | |
| $167 | +1.72% | +12.61% | +21.77% | The five-year strategic transition concludes with normalized earnings compounding on a rebuilt, multi-pillar commercial foundation. Valuation multiples settle near industry parity, delivering measured capital appreciation alongside a reliable dividend return. | $97.2 | $209 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Merck & Stock Analysis & Scenarios Deep Dive
Merck &: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? The prevailing market belief is that the late-2028 Keytruda patent cliff is an existential threat to earnings, yet the stock is treated as a safe dividend fortress. Consensus fixates on dramatic first-half 2026 GAAP losses as evidence of fundamental decay, while assuming that high trailing price-to-earnings multiples reflect structural overvaluation rather than non-recurring accounting charges tied to strategic acquisitions.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd overestimates the destructive speed of the patent cliff while underestimating underlying cash power. The decisive overlooked evidence is that first-half 2026 net losses were caused entirely by fourteen point seven billion dollars in upfront acquired research charges for Cidara and Terns, not operating weakness. Normalized free cash flow exceeds sixteen billion dollars, while subcutaneous Keytruda Qlex adoption and Winrevair expansion provide substantial revenue replacement invisible in headline multiples.
Repricing Catalyst
What could make the market recognize and close that gap? The primary catalyst is the clean reporting of late 2026 and 2027 earnings devoid of upfront deal charges, which will restore reported GAAP metrics to operational cash reality. Concurrently, commercial updates showing subcutaneous Keytruda conversion surpassing twenty-five percent alongside Winrevair exceeding three billion dollars in annualized run-rate sales by late 2027 will force sell-side analysts to revise terminal cash flows upward.
Merck &: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Balanced
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Growing Awareness
Sentiment splits between value-oriented confidence in sixteen billion dollars of free cash flow and acute institutional anxiety over late-2028 patent expiration. The decisive tension centers on whether subcutaneous switching preserves cash flows or payer step-therapy mandates trigger sharp multiple compression.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regime of persistent inflation and high policy rates presents a mixed setup. Non-discretionary medical demand and pricing power insulate operational cash flows from stagflation, driving defensive equity rotation. However, elevated benchmark borrowing yields increase capital costs for future debt-financed acquisitions and exert downward pressure on long-duration pharmaceutical valuation multiples.
Advisor Disagreement
What do our AI Advisors disagree about most? The central debate divides analysts on whether subcutaneous Keytruda Qlex provides an enduring commercial moat or merely a transient delay before generic commoditization. Bullish views assume oncology practices and patients will stick to the convenience of two-minute subcutaneous dosing, converting over thirty-five percent of volume. Bearish frameworks counter that aggressive commercial payers and Medicare will enforce step-therapy favoring sixty percent discounted intravenous biosimilars. Tracking commercial payer formulary exclusions and actual clinic conversion percentages through 2027 will conclusively resolve whether the patent transition represents a manageable incline or a destructive cliff.
Merck &: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Subcutaneous Keytruda Qlex formulation lifecycle defense | Innovation And Product | +16% | +20% | Subcutaneous pembrolizumab co-formulated with berahyaluronidase alfa compresses hospital chair time from forty minutes to two minutes. By migrating thirty to forty percent of oncology volume before late-2028 intravenous patent expiration, newly granted secondary formulation patents protect high-margin biologic cash flows through the mid-2030s, blunting immediate generic biosimilar volume erosion. |
| Winrevair pulmonary arterial hypertension commercial expansion | Competitive Positioning | +14% | +18% | Sotatercept establishes a first-in-class, disease-modifying treatment in pulmonary arterial hypertension, surging seventy-five percent year-over-year to five hundred eighty-eight million dollars in second-quarter 2026. Global label expansions and stellar morbidity data position the asset to capture four to six billion dollars in peak non-oncology revenue, diversifying corporate earnings. |
| Cardiometabolic and antibody conjugate pipeline commercialization | Innovation And Product | +11% | +13% | The commercial launch of Lipfendra as the first oral daily PCSK9 inhibitor, alongside pivotal clinical progression across Kelun and Daiichi Sankyo antibody-drug conjugate alliances, establishes multi-pillar replacement revenue. These differentiated therapies access large primary care and refractory oncology indications, rebuilding top-line growth capacity. |
| Defensive free cash flow capital allocation | Capital Allocation | +9.0% | +10% | Generating sixteen billion dollars in trailing free cash flow provides immense financial flexibility. Management consistently supports an eight billion dollar annual dividend commitment alongside programmatic share repurchases and targeted licensing deals, establishing a durable total-return floor that buffers shareholder equity against broader macroeconomic volatility. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Intravenous pembrolizumab composition patent expiration cliff | Competitive Positioning | -21% | -27% | Keytruda generates thirty-one point seven billion dollars annually, representing nearly half of consolidated group sales. Core United States patent expiration in late 2028 invites aggressive biosimilar competition, triggering mandatory price discounting and significant volume erosion across institutional hospital channels that cannot be fully offset by new product launches. |
| Inflation Reduction Act Medicare price negotiation | Regulatory | -11% | -14% | Statutory drug price negotiation mandates under the Inflation Reduction Act target top-expenditure Part B biologics starting in 2028. Government-enforced ceiling prices will force deep mandatory discounts on pembrolizumab, permanently degrading domestic oncology gross margins and restricting management's historical ability to offset volume losses with list-price increases. |
| Dilutive upfront acquired research accounting drag | Capital Allocation | -8.0% | -11% | Aggressive business development requires substantial capital deployment, expensing fourteen point seven billion dollars in upfront acquired research during early 2026 for Cidara and Terns. While backfilling pipeline assets, high purchase premiums and recurring milestone obligations depress reported return on invested capital and elevate near-term financial leverage. |
| Gardasil international vaccine demand structural deceleration | Sector And Industry | -7.0% | -9.0% | Gardasil sales dropped thirty-nine percent in 2025 due to Chinese distributor inventory adjustments, local anti-corruption campaigns, and cheaper domestic competitive vaccines. The removal of minimum procurement obligations in key Asian channels permanently impairs a formerly high-growth earnings pillar, eliminating a critical cash-flow cushion ahead of oncology patent transitions. |
Merck &: What Could Break or Accelerate the Thesis
Event Risk Score: Low 36/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Subcutaneous Keytruda formulation patent judicial invalidation | 26% | -28% | Consolidated patent litigation or antitrust challenges by biosimilar syndicates could successfully invalidate secondary formulation patents defending Keytruda Qlex prior to 2028. Siding with generic challengers would clear bioequivalent subcutaneous alternatives for immediate launch, vaporizing the intended volume conversion shield and precipitating severe top-line revenue destruction. |
| Winrevair post market safety signal emergence | 18% | -20% | The emergence of unanticipated systemic or vascular toxicities during post-marketing surveillance across broader pulmonary arterial hypertension populations could prompt regulatory black-box warnings. Restrictive labeling would throttle clinician adoption and derail label expansion into heart failure, dismantling the primary non-oncology growth pillar relied upon to replace off-patent revenues. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Subcutaneous Keytruda patent estate comprehensive judicial validation | 32% | +24% | Federal appellate courts and international patent offices could comprehensively uphold formulation and co-delivery patents covering Keytruda Qlex through 2035, barring generic subcutaneous market entry. This judicial outcome would allow the company to transition over fifty percent of oncology volume into protected administration, preserving billions in high-margin cash flow and triggering aggressive equity multiple expansion. |
| Breakthrough Phase 3 survival data across partnered ADCs | 28% | +20% | Pivotal Phase 3 trials for sacituzumab tirumotecan and Daiichi-partnered antibody-drug conjugates demonstrating statistically superior overall survival in first-line lung and breast cancers would unlock expedited regulatory approvals. Capturing broad multi-indication oncology market share would generate over eight billion dollars in high-margin peak revenue, neutralizing patent cliff fears well ahead of schedule. |
Company Financial AnalysisMerck &: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Merck & financials here.
Earnings and financials
Reported accounting numbers show a confusing contrast between headline losses and underlying business strength. In early 2026, the company posted quarterly net losses despite sales rising five percent to sixteen point six billion dollars. These paper losses occurred because accounting rules required writing off fourteen point seven billion dollars immediately for acquiring biotech innovators Cidara and Terns. Beneath this accounting noise, everyday financial performance remains exceptionally strong. The core business generated over sixteen billion dollars in trailing free cash flow, supported by growing Keytruda sales and the fast uptake of Winrevair. As one-time acquisition write-offs end, reported corporate earnings will quickly realign with underlying cash generation.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 64.9B | USD 18.3B | USD 12.4B |
| 2024 | USD 64.2B | USD 17.1B | USD 18.1B |
| 2023 | USD 60.1B | USD 365M | USD 9.1B |
| 2022 | USD 59.3B | USD 14.5B | USD 14.7B |
| 2021 | USD 48.7B | USD 13B | USD 9.7B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 14.3x | TTM | Native | USD / USD |
| 2024 | 14.8x | TTM | Native | USD / USD |
| 2023 | >100x | TTM | Native | USD / USD |
| 2022 | 19.5x | Annual | Native | USD / USD |
| 2021 | 14.9x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Gross profit margins remain structurally elite above seventy-two percent, demonstrating formidable pricing power in complex cancer medicines and specialized vaccines. While reported operating margins turned temporarily negative due to upfront acquisition charges, underlying operational profit margins consistently exceed thirty-five percent. However, this exceptional profitability faces long-term structural pressure. As cheaper biosimilars enter the market post-2028 and newer therapies carry higher partner royalties, corporate gross margins will gradually compress toward sixty-five percent, establishing a lower steady-state margin baseline for the next decade.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 23.5B | 36.2% | 28.1% |
| 2024 | USD 20.2B | 31.5% | 26.7% |
| 2023 | USD 3B | 4.9% | 0.6% |
| 2022 | USD 18.3B | 30.8% | 24.5% |
| 2021 | USD 13.2B | 27.1% | 26.8% |
Balance sheet and leverage
The corporate balance sheet represents a sturdy financial fortress designed to endure patent transitions. At year-end 2025, total assets reached one hundred thirty-seven billion dollars against fifty-two point six billion dollars in equity, with a conservative debt-to-equity ratio of zero point ninety-six and strong interest coverage above sixteen times. Recent debt-funded acquisitions and rising interest rates have elevated borrowing costs, but immense operating cash flows provide complete safety. Management holds sufficient financial headroom to support an uninterrupted eight point two billion dollar annual dividend commitment while funding essential clinical pipeline trials.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 50.5B | USD 14.6B | USD 36B net debt | USD 36B | 1.54x |
| 2024 | USD 38.3B | USD 13.7B | USD 25B net debt | USD 24.6B | 1.36x |
| 2023 | USD 36.3B | USD 7.1B | USD 29.4B net debt | USD 29.2B | 1.25x |
| 2022 | USD 32B | USD 13.2B | USD 19.3B net debt | USD 18.8B | 1.47x |
| 2021 | USD 34.6B | USD 8.1B | USD 26.5B net debt | USD 26.5B | 1.27x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Physical factory investment remains disciplined, consuming roughly six percent of sales for modernizing biologic manufacturing plants and sterile injection lines. This predictable spending keeps physical production efficient without placing excess strain on corporate cash reserves. Instead, real capital intensity is concentrated in external deal-making. Management spent billions in cash to purchase late-stage drug pipelines, trading temporary accounting profits for vital replacement therapies needed before 2028. Success requires these purchased programs to convert into launched commercial blockbusters before the primary patent expires.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 4.1B | USD 12.5B |
| 2024 | USD 3.4B | USD 17.9B |
| 2023 | USD 3.9B | USD 30.5B |
| 2022 | USD 4.4B | USD 13.5B |
| 2021 | USD 4.4B | USD 12.2B |
Behind the synthesisMerck &: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The analysis reveals high consensus on two foundational facts: headline GAAP losses stem entirely from fourteen point seven billion dollars in upfront acquired research write-offs rather than operational decay, and core cash flow remains robust near sixteen billion dollars. However, sharp divergence exists regarding post-2028 terminal valuation. Bullish perspectives argue subcutaneous formulation conversion and cardiopulmonary launches fully insulate group revenues. Conversely, the contrarian view demonstrates that recent valuation expansion was driven by defensive rotation amid sticky inflation and high benchmark yields, not earnings growth. Keytruda generates nearly half of group sales, meaning statutory price negotiations and biosimilar discounting cannot be fully neutralized by secondary formulations if commercial payers mandate cheaper intravenous alternatives. Consequently, weights prioritize reports providing rigorous forensic separation of GAAP distortion from recurring owner earnings while penalizing both uncritical soft-landing assumptions and overly catastrophic liquidation scenarios.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 12.5%
Exhibits superior primary-source forensic accounting from SEC filings, meticulously separating non-recurring acquired research charges from organic earnings power. Soundly models debt obligations, royalty termination benefits, and realistic net price erosion curves post-2028.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 11.5%
Provides rigorous analysis of valuation multiple expansion occurring on stagnant underlying earnings alongside defensive rotation. Detailed dissection of the upcoming CMS subcutaneous drug negotiation timeline, net debt realities, and post-cliff revenue replacement economics warrants an above-average weight.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.6%
Grounded in disciplined owner-earnings methodology, accurately demonstrating that trailing free cash flow exceeding sixteen billion dollars protects intrinsic value despite GAAP optical losses. Appropriately tempers terminal valuation multiples against patent cliff frictions.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.6%
Demonstrates excellent forensic precision in reconciling headline GAAP losses with operational reality, tracing fourteen point seven billion dollars of upfront deal write-offs. Provides credible commercial tracking data for subcutaneous pembrolizumab and rare-disease expansion.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.7%
Applies rigorous first-principles logic to the thermodynamic difficulty of replacing a thirty-two billion dollar single-molecule monopoly. Correctly highlights capital allocation dilution from speculative biotech deal-making while recognizing near-term cardiopulmonary scaling.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.7%
Offers a coherent macro regime alignment framework, illustrating how elevated sovereign yields and inflation drive defensive rotations into inelastic biopharma cash flows. Its post-cliff growth trajectory, however, assumes slightly too frictionless a commercial transition.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Presents strong insight into institutional lifecycle management and formulation hopping mechanics for pembrolizumab. However, it displays mild over-optimism regarding regulatory insulation and underestimates systemic resistance from federal antitrust and commercial healthcare payers.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Provides thoughtful synthesis of physician behavioral inertia, clinic workflow economics, and subcutaneous formulation adoption. It appropriately balances non-oncology growth assets like Winrevair against structural international vaccine procurement deceleration.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Presents a compelling perspective on biopharmaceutical scale and commercial execution firepower. However, it understates payer resistance to premium subcutaneous formulations and models an overly aggressive valuation rerating across the post-2028 horizon.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.8%
Delivers balanced cash-flow sensitivity modeling and distinguishes reported upfront collaboration accounting hits from recurring operational cash conversion. It moderately underplays terminal multiple compression risks as biosimilar entry dates approach.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.8%
Correctly identifies the continuous treadmill of costly external pipeline acquisitions required to replace expiring biologic revenues. However, it overstates long-term operating margin degradation by dismissing high gross margin contributions from newly launched specialty therapies.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.8%
Offers a disciplined assessment of the margin of safety at current valuation multiples, properly cautioning against multiple compression. It somewhat discounts the substantial defensive buffer provided by rapid subcutaneous clinic conversion.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.8%
Constructs a competent analysis of the multi-layered commercial defense across cardiometabolic and oncology pipelines. It shares significant analytical correlation with other universal frameworks while adding fewer distinctive forensic observations.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 2.9%
Serves as an aggressive contrarian reality check on structural revenue concentration, China Gardasil impairment, and PBM step-therapy mandates. The projected thirty-five percent equity collapse, however, ignores resilient sixteen billion dollar cash flows and proven subcutaneous switching.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Merck & forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web36 available sources from this batch (208 recorded). The first 15 are shown below; expand to read the rest.
- Fact Sheet: Medicare Drug Price Negotiation Program June 2023 cms.gov
- FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol | FDA fda.gov
- https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/ex991q420258-k.htm?utm_source=openai sec.gov
- Merck & Co., Inc. - Form 10-Q - FY2026 sec.gov
- Merck & Co., Inc. - Form 8-K - FY2026 sec.gov
- mrk-20251231 sec.gov
- Merck (MRK) Stock Price Prediction: 2025, 2026, 2030 benzinga.com
- Medicare drug price rule may target under-the-skin Keytruda and Opdivo | BioPharma Dive biopharmadive.com
- Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline - BioSpace biospace.com
- Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline businesswire.com
- Merck (MRK) earnings Q2 2026 cnbc.com
- Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline cnbc.com
- MRK Stock Quote Price and Forecast | CNN cnn.com
- Merck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise Targets finance.yahoo.com
- Medicare drug price rule may target under-the-skin cancer immunotherapies | Healthcare Dive healthcaredive.com
Show 21 more sources
- Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches invezz.com
- Mercks & Co's sprint against the KEYTRUDA patent cliff: will it cross the finish line? kletthamerinsights.com
- Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs - MedCity News medcitynews.com
- - 11 - **Upcoming Investor Event** The Company merck.com
- Data-rich period ahead with multiple Phase 3 readouts across novel mechanisms merck.com
- Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline - Merck.com merck.com
- Merck Completes Acquisition of Terns Pharmaceuticals, Inc. - Merck.com merck.com
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia - Merck.com merck.com
- Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Merck.com merck.com
- MRK 03.31.2026 10Q merck.com
- MRK 06.30.2026 10Q merck.com
- Q2 2026_Earnings_Infographic_MRK merck.com
- How Much Does Keytruda Cost in 2026? List Price, Insurance, Medicare & Medicaid refillrelay.com
- June 1, 2026 s21.q4cdn.com
- Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff (NYSE:MRK) | Seeking Alpha seekingalpha.com
- Merck (NYSE:MRK) - Stock Analysis - Simply Wall St simplywall.st
- Merck & Co. (MRK) Stock Price & Overview stockanalysis.com
- Merck 2026 Outlook: Keytruda Patent Cliff, Pipeline Strategy & Competitive Intelligence | SyneticX syneticx.com
- Merck (MRK) Q2 2026 Earnings Call Transcript - The Globe and Mail theglobeandmail.com
- How Much Does Keytruda Cost with Insurance in the U.S. (2026 Update) | Real Prices, Coverage & Savings Tips untravel.info
- Keytruda Cost 2026: Price Per Dose, Medicare Coverage & $25 Copay Program untravel.info
172 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.